Summary:
Hematopoietic chimerism (HpC) was assayed monthly using a sensitive, polymerase chain reaction (PCR) -based method in consecutive patients. Between January 1998 and April 2002, 181 patients underwent non-T cell depleted allogeneic hematopoietic cell transplantation (HCT). A total of 163 patients were evaluable for HpC at 1 month (11 early deaths; no informative band for HpC analysis/no genomic DNA in seven). In all, 53 of 163 patients (33%, median recipient DNA of 15% (range 5–95)), 39 of 151 patients (26%), and 27 of 142 patients (19%) showed mixed chimerism (MC) at 1, 2, and 3 months after HCT, respectively. Conditioning regimen (busulfan-fludarabine–ATG vs BuCy, relative risk 3.99 (95% CI 1.16–10.92)), neutrophil engraftment (⩾day 17 vs ⩽day 16, relative risk 2.49 (95% CI 1.14–5.41)), and acute graft-versus-host disease within 30 days (none vs yes, relative risk 4.78 (95% CI 1.50–15.17)) were independent variables that showed significant correlation with having ⩾5% recipient DNA at 1 month. Five patients experienced secondary graft failure. All five patients showed MC at 1 month with median recipient DNA of 40%. None of the 109 patients with complete chimerism experienced graft failure (P=0.002). Our study showed that MC shown on monthly analysis of HpC after allogeneic HCT is a significant predictor of secondary graft failure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dubovsky J, Daxberger H, Fritsch G et al. Kinetics of chimerism during the early post transplant period in pediatric patients with malignant and non malignant hematologic disorder: implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13: 2060–2069.
Thiede C, Bornhäuser M, Oelschlägel U et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001; 15: 293–302.
Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune response. Blood 1999; 94: 3234–3241.
Scharf SJ, Smith AG, Hansen JA et al. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995; 85: 1954–1963.
Roux E, Helg C, Chapuis B et al. Evolution of mixed chimerism after allogeneic bone marrow transplantation as determined on granulocyte and mononuclear cells by the polymerase chain reaction. Blood 1992; 79: 2775–2783.
Choi S-J, Lee K-H, Lee J-H et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 2000; 26: 327–332.
Thiede C, Florek M, Bornhäuser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.
van Leeuwen JEM, van Tol MJD, Joosten AM et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 1994; 83: 3059–3067.
Molloy K, Goulden N, Lawler M et al. Patterns of hematopoietic chimerism following bone marrow transplantation for childhood acute lymphoblastic leukemia from volunteer unrelated donors. Blood 1996; 87: 3027–3031.
Hills RS, Petersen FB, Storb R et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811–816.
Frassoni F, Strada P, Sessarego M et al. Mixed chimerism after allogeneic marrow transplantation for leukaemia: correlation with dose of total body irradiation and graft-versus-host disease. Bone Marrow Transplant 1990; 5: 235–240.
Roy DC, Tantravahi R, Murray C et al. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood 1990; 75: 296–304.
Mackinnon S, Barnett L, Bourhis JH et al. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235–3241.
Bertheas MF, Lafage M, Levy P et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood 1991; 78: 3103–3106.
Roux E, Helg C, Chapius B et al. Mixed chimerism after bone marrow transplantation and the risk of relapse. Blood 1994; 84: 4385–4386 (letter).
Mackinnon S, Barnett L, Heller G, O'Reilly RJ . Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 3409–3416.
Serrano J, Roman J, Herrera C et al. Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse. Bone Marrow Transplant 1999; 23: 475–482.
Wäsch R, Bertz H, Kunzmann R, Finke J . Incidence of mixed chimerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Hematol 2000; 109: 743–750.
Bader P, Holle W, Klingebiel T et al. Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 1997; 19: 697–702.
Ramirez M, Diaz MA, Garcia-Sanchez F et al. Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia. Bone Marrow Transplant 1996; 18: 1161–1165.
Bader P, Beck J, Frey A et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487–495.
Suttorp M, Schmitz N, Dreger P et al. Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms. Leukemia 1993; 7: 679–687.
Lee J-H, Lee K-H, Lee J-H et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with bulsulfan and cyclophosphamide. Br J Hematol 2002; 118: 1087–1094.
Lee J-H, Lee K-H, Choi S-J et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 2000; 26: 657–662.
Lee K-H, Lee J-H, Lee J-H et al. Non myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation. Haematologica 2001; 86: 999–1001.
Przepiorka D, Weisdorf D, Martin P et al. Meeting report. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Sullivan KM . Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4: 42–93.
McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.
Bearman SI, Anderson GL, Mori M et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729–1736.
Edwards A, Civitello A, Hammond HA, Caskey CT . DNA typing and genetic mapping with trimeric and tetrameric tandem repeats. Am J Hum Genet. 1991; 49: 746–756.
Schlotterer C, Tautz D . Slippage synthesis of simple sequence DNA. Nucleic Acids Res 1992; 20: 211–215.
Acknowledgements
The work was supported in part by a grant of the 1999 Korean National Cancer Control Program, Ministry of Health and Welfare, Republic of Korea.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, KH., Lee, JH., Choi, SJ. et al. Monthly prospective analysis of hematopoietic chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 32, 423–431 (2003). https://doi.org/10.1038/sj.bmt.1704147
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704147
Keywords
This article is cited by
-
Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility
Bone Marrow Transplantation (2007)
-
Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and nonmyeloablative stem cell transplantation
Bone Marrow Transplantation (2006)
-
Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study
Bone Marrow Transplantation (2005)
-
Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation – frequency and outcomes
Bone Marrow Transplantation (2004)
-
Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study
Bone Marrow Transplantation (2004)